Powered by
MOMENTUM
MEDIA
NYSE-listed Ginkgo Bioworks (NYSE: DNA) has entered into a technical development agreement with ASX-listed Microba Life Sciences (ASX: MAP).
Firm: MinterEllison (Ginkgo Bioworks)
Area: Capital markets
Value: N/A
Key players: The Minter team was led by partner James Hutton, who was supported by corporate specialist Esmond Prowse and a cross-disciplinary MinterEllison team comprising specialists in intellectual property, tax, foreign investment, trade and transaction solutions.
Deal significance: Mr Hutton said: “We’re delighted to support Ginkgo in this transaction to help them work towards their collaboration and great health outcomes for the community.
“The pandemic has continued to put a spotlight on the importance of life sciences and biotech for the wellbeing of the global community. Global partnerships like Ginkgo and Microba’s are a great example of how organisations are harnessing this to rapidly develop and improve diagnostics and treatment options.
“This also continues a theme of the growing importance of utilising computer power in life science platform technologies.”
Jerome Doraisamy is the managing editor of Lawyers Weekly and HR Leader. He is also the author of The Wellness Doctrines book series, an admitted solicitor in New South Wales, and a board director of the Minds Count Foundation.
You can email Jerome at:
Login
